VEGFA and hypertensive disorder: Increased risk of hypertension has been seen in 25% of patients on this regimen, as well as uncontrolled hypertension linked to further adverse effects such as reversible posterior leukoencephalopathy and proteinuria, which occasionally leads to a permanent cessation of VEGF inhibitor therapy and, consequently, causes protein reduction (up to 3 g protein loss in 24 h) [61].